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margin = 2.25mm (Range 1.25-3mm). Median PTV volume = 32cc 
(Range= 6-1879cc).Prescription dose was 30-36Gy in 3-5# (BED using 
α/β=10, 48-79). Dose was prescribed to the Median 64% isodose line 
(Range 48-78%). Median coverage was 98.3% (range 95.2-99.9%). 
Treatment delivery was tracked with fiducials and the Synchrony 
system. 
Results: Outcome data was available for 10 patients. Local Control 
rate was 100%. 4 patients (40%) progressed distantly, 2 in the IMC 
Node group, and 2 in the Sternum group. One of the patients that 
progressed distantly in the Sternal group had distant disease at the 
time of CyberKnife. Of those that progressed distantly, 75% had 
received chemotherapy as their first treatment at the time of 
Sternal/IMC node recurrence. Median Disease-Free Interval (DFI) in 
progressors was 2 years (Range 1-6 yrs), compared to a DFI in Non-
progressors of 3 years (Range 1-13 yrs). Median Progression-Free 
Survival for the IMC node group, Sternal group, and Cohort as a whole 
were 6, 2 and 4 months respectively. The follow-up data was, 
however, less mature for the Sternal group. Overall Survival (OS) rate 
was 90%. The patient that died was had Sternal recurrence patient 
with small lung metastases at the time of CyberKnife treatment. She 
died of lepto-meningeal disease. Median OS for IMC node group, 
Sternal group and Cohort as a whole were 16, 2 and 6 months 
respectively. However, follow-up data is less mature for the Sternal 
group. Treatment was well tolerated with only 25% of the group 
experiencing acute toxicity (G1). Only 1 patient experienced Late 
toxicity (fleeting G3 symptoms), the patient had received prior 
rdaiotherapy. 
Conclusions: SBRT is a feasible treatment approach for patients with 
Sternal/IMC nodal recurrence of Breast Cancer. The technique is well 
tolerated, even in those who have received prior Radiotherapy. The 
outcome data is still immature, but the early Local Control rates 
(100%), and Overall Survival rates (90%) at a Median follow-up of 11 
months are encouraging.  
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Purpose/Objective: The management of disease recurrence within a 
previously irradiated pelvic field is a challenging clinical problem. The 
ability to re-irradiate the pelvis to a therapeutically meaningful dose 
is limited by the cumulative dose received by adjacent pelvic organs 
at risk (OAR). The Cyberknife radiosurgery system enables highly 
conformal dosimetry with rapid dose fall off outside of the target. 
This, in combination with the use of small treatment margins 
facilitated by tumour tracking, make it a potentially attractive 
delivery platform for re-irradiation. 
The aim of this retrospective study was to review the toxicity and 
early efficacy data of patients receiving SBRT with the Cyberknife 
platform for pelvic re-irradiation at our institution. 
Materials and Methods: Patients receiving Cyberknife SBRT to 
abdominopelvic targets sited within a previously irradiated field were 
retrospectively identified. Details on primary site histology, prior 
external beam radiotherapy (EBRT), re-irradiation dose and indication 
for re-treatment were obtained from the patient’s electronic notes. 
Radiotherapy toxicity was graded using CTCAE v4.0. Follow up 
consisted of clinical examination and radiological assessment. In field 
local control and time to progression were calculated from the day of 
completing SBRT until the date of radiological evidence of progression 
using standard RECIST criteria. 
Results: 16 patients were treated between 01.08.11-01.11.12. Median 
follow up was 6 months (range 1-15). 8 patients had primary 
gynaecological malignancies, 7 colorectal and 1 melanoma. Median 
age was 59 years (range 27-85). Indications for re-irradiation were 
nodal recurrence (6), soft tissue recurrence (7) and positive margins 
following surgery (3). Median time from previous EBRT was 20 months 
(range 1-156). Median previous EBRT dose was 50.4 Gy (range 30-54) 
in 28 fractions (range 10-39). 3 patients with gynaecological primaries 
had also received prior brachytherapy. Median re-irradiation dose was 
30 Gy (range 18-35) in 3 fractions. 44% of patients had no recordable 
toxicity. 3 patients with pelvic side wall recurrences experienced G2 
pain during treatment, which resolved shortly after completion of 
SBRT. One patient developed a colovesical fistula 2 months after SBRT 
(G4 toxicity). This was associated with local disease recurrence 
therefore the aetiology was unclear. At last follow up, local control is 
94% (15/16 patients). A single patient had an in field recurrence 2 
months after SBRT. 6/16 patients (38%) have relapsed at distant sites. 
Median time to relapse at any site was 3 months (range 2-11). 
Conclusions: At this early time point of data analysis, minimal toxicity 
has been observed to date. Cyberknife SBRT is a promising method for 
pelvic re-irradiation and warrants further investigation.  
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Purpose/Objective: The use of autosegmentation computed systems 
in clinical setting for locally advanced rectal cancer is time sparing 
with an acceptable Dice Coefficient for CTV, Mean Dice Coefficient 
(MDC) of 0.70, while it does not reach an adequate value for small 
nodal subvolumes (MDC=0.67) (1). In this phase II study the objective is 
to verify in clinical setting the time sparing and the Dice Coefficient in 
bigger volumes (CTV and grouped nodal subvolumes) in locally 
advanced rectal cancer using the Smart Segmentation Knowledge 
Based Contouring (SS-KBC)® research program.  
(1) Clinical validation of atlas-based auto-segmentation of pelvic 
volumes and normal tissue in rectal tumors using autosegmentation 
computed system. Gambacorta et al, Acta Oncologica, in press 
Materials and Methods: 29 consecutive patients were selected 
between June and September 2012; images of 14 patients as atlas, 15 
for validation. To test the reliability of the system for bigger volumes, 
the nodal subvolumes were grouped according to clinical stage and 
site of the tumor (tab1). According to our ongoing QA program two 
operators were involved: a Delineator and a Reviewer. CTV and pelvic 
grouped nodal subsites were contoured by Delineator in 2 different 
sequences (A-manual vs B-autosegmentation) of contouring using the 
same planning CT; all of them underwent to Indipendent Check by 
Reviewer. To improve the reliability of the system many 
anthropometric characteristics where analyzed (including BMI, sex, 
age, fertility state, sacro-coccigeal distance and the most anterior 
distance between upper iliac crests). The analysis was conducted to 
test the reliability of the system using Dice Coefficient and the total 
time spared by the Delineator to complete the 2 different sequences. 
 
 
Results: In clinical practice the time spared by operator 1 to complete 
sequence A and B was of 14min vs 1min respectively; there was a 
statistically significant better MDC in favor of sequence A vs sequence 
B: 
-CTV: sequence A (MDC=0.86) vs sequence B (MDC=0.78), p=0.001 
(fig.1) 
-Subvolume 1: sequence A (MDC=0.86) vs sequence B (MDC=0.77), 
p=0.001 
-Subvolume 2a: sequence A (MDC=0.76) vs sequence B (MDC=0.66), 
p=0.001 
